Filing Flows › Xenetic Biosciences (XBIO) › Q1 2025
Xenetic Biosciences (XBIO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Xenetic Biosciences (XBIO) reported revenue of $593K for the first quarter 2025 (Q1 2025), +16% from a year earlier and -9% from the quarter before. Operating margin was -158.9%, net loss $903K (152.2% of revenue).
Xenetic Biosciences, Q1 2025: revenue $593K (+16% year over year), operating margin -158.9%, net loss $903K, operating cash flow −$1.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $593K | -9% | +16% |
| Operating profit | −$942K | — | — |
| Net earnings | −$903K | — | — |
| Operating cash flow | −$1.0M | — | — |
What changed
Revenue was $593K in Q1 2025, up 16% year over year and down 9% from the previous quarter.
Operating costs exceeded revenue by $942K, an operating margin of -158.9%. Total costs fell 14% while revenue rose 16%. The quarter ended with a net loss of $903K, narrower than the previous quarter's $1.1M loss.
Operating cash flow was −$1.0M. Non-cash charges added back $19K of share-based compensation. Working capital and other items used $118K.
Questions
What was Xenetic Biosciences' revenue in the first quarter 2025?
Xenetic Biosciences (XBIO) reported revenue of $593K for the first quarter 2025 (Q1 2025), +16% from a year earlier and -9% from the quarter before.
Was Xenetic Biosciences profitable in the first quarter 2025?
Operating loss was $942K (-158.9% of revenue) and net loss $903K.